Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Raffaella Franca, Debora Curci, Marianna Lucafò, Giuliana Decorti & Gabriele Stocco. (2019) Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 15:7, pages 527-539.
Read now
Read now
Samuele Naviglio, Paolo Giuffrida, Gabriele Stocco, Marco Vincenzo Lenti, Alessandro Ventura, Gino Roberto Corazza & Antonio Di Sabatino. (2018) How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 12:8, pages 797-810.
Read now
Read now
Karen van Hoeve, Ilse Hoffman & Severine Vermeire. (2018) Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opinion on Drug Safety 17:2, pages 185-196.
Read now
Read now
Articles from other publishers (35)
Joelynn Dailey & Jeffrey S. Hyams. 2023. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
103
111
.
Sally Lawrence, Farah Faytrouni, Rachel E. Harris, Mike Irvine, Estefania Carrion, Gregor Scott, Benjamin Clarke, Vikki Garrick, Lee Curtis, Lisa Gervais, Rachel Tayler, Marliss Riou, Richard Hansen, Kevan Jacobson & Richard K. Russell. (2022) Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing. Journal of Pediatric Gastroenterology & Nutrition 75:5, pages 601-607.
Crossref
Crossref
Hsuan Ping Chang, Valentina Shakhnovich, Adam Frymoyer, Ryan Sol Funk, Mara L. Becker, K. T. Park & Dhaval K. Shah. (2021) A population physiologically‐based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. British Journal of Clinical Pharmacology 88:1, pages 290-302.
Crossref
Crossref
A. Nassar-Sheikh Rashid, D. Schonenberg-Meinema, S. C. Bergkamp, S. Bakhlakh, A. de Vries, T. Rispens, T. W. Kuijpers, G. Wolbink & J. M. van den Berg. (2021) Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). Pediatric Rheumatology 19:1.
Crossref
Crossref
Akshay Kapoor & Eileen Crowley. (2021) Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Frontiers in Pediatrics 9.
Crossref
Crossref
Sara Salvador‐Martín, Gemma Pujol‐Muncunill, Ferran Bossacoma, Víctor Manuel Navas‐López, Carmen Gallego‐Fernández, Oscar Segarra, Susana Clemente, Rosana Muñoz‐Codoceo, Javier Viada, Lorena Magallares, Eva Martínez‐Ojinaga, Ana Moreno‐Álvarez, Alfonso Solar‐Boga, Inés Loverdos, Vicente Merino‐Bohórquez, María Jesús Balboa‐Vega, Alejandro Rodriguez‐Martinez, Concepción Alvarez‐Vayo, Cesar Sanchez, Mar Tolin, José Antonio Blanca‐García, Ruth García‐Romero, Francisco Javier Eizaguirre, José Germán Sánchez‐Hernandez, Rafael Gonzalez Caldas, Antonio Millán‐Jimenez, Elena Aznal, Judith Abarca‐Zabalía, María Sanjurjo‐Sáez & Luis Andrés López‐Fernández. (2020) Pharmacogenetics of trough serum anti‐TNF levels in paediatric inflammatory bowel disease. British Journal of Clinical Pharmacology 87:2, pages 447-457.
Crossref
Crossref
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine & Frank M Ruemmele. (2021) The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 15:2, pages 171-194.
Crossref
Crossref
Mihika B. Dave, Alpa J. Dherai, Devendra C. Desai, Diane R. Mould & Tester F. Ashavaid. (2020) Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach—an Indian experience. European Journal of Clinical Pharmacology 77:1, pages 55-62.
Crossref
Crossref
Mihika B. Dave, Alpa J. Dherai, Devendra C. Desai, Bhamini G. Keny, Dhanashri N. Shetty, Satish Kulkarni, Kiran Peddy & Tester F. Ashavaid. (2020) Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit. Indian Journal of Gastroenterology 39:5, pages 426-434.
Crossref
Crossref
Isabel Pinto Pais, Maria C. Espinheira, Eunice Trindade & Jorge Amil Dias. (2020) Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. Journal of Pediatric Gastroenterology & Nutrition 71:1, pages 12-18.
Crossref
Crossref
Dwight A. Winter, Maria E. Joosse, Saskia N. de Wildt, Jan Taminiau, Lissy de Ridder & Johanna C. Escher. (2020) Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations. Journal of Pediatric Gastroenterology & Nutrition 70:6, pages 763-776.
Crossref
Crossref
Olivier Courbette, Camille Aupiais, Jérôme Viala, Jean-Pierre Hugot, Xavier Roblin, Sophie Candon, Baptiste Louveau, Lucienne Chatenoud & Christine Martinez-Vinson. (2020) Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology & Nutrition 70:3, pages 310-317.
Crossref
Crossref
Mario RegazziJoseè Golay & Mariadelfina Molinaro. (2020) Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. Therapeutic Drug Monitoring 42:1, pages 45-56.
Crossref
Crossref
Joshua M. Steinberg & Aline Charabaty. (2020) The Management Approach to the Adolescent IBD Patient: Health Maintenance and Medication Considerations. Current Gastroenterology Reports 22:1.
Crossref
Crossref
Vasilije Novakovic, Samire Abdija, Pia Bükmann Larsen, Mogens Fenger, Lene Gredal & Katja Kemp Jacobsen. (2019) Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels. Clinical Biochemistry 74, pages 73-75.
Crossref
Crossref
Yoel Gofin, Manar Matar, Raanan Shamir & Amit Assa. (2019) Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease. Inflammatory Bowel Diseases.
Crossref
Crossref
Debora Curci, Marianna Lucafò, Adriana Cifù, Matteo Bramuzzo, Stefano Martelossi, Diego Favretto, Francesca De Pellegrin, Martina Fabris, Fulvia Vascotto, Samuele Naviglio, Alessandro Ventura, Gabriele Stocco & Giuliana Decorti. (2019) Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 69:4, pages 474-479.
Crossref
Crossref
Ben Kang, So Yoon Choi, Young Ok Choi, Soo-Youn Lee, Sun-Young Baek, Insuk Sohn, Byung-Ho Choe, Hae Jeong Lee & Yon Ho Choe. (2019) Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease. Journal of Crohn's and Colitis 13:2, pages 189-197.
Crossref
Crossref
Samuele Naviglio, Doriana Lacorte, Marianna Lucafò, Adriana Cifù, Diego Favretto, Eva Cuzzoni, Tania Silvestri, Martina Pozzi Mucelli, Oriano Radillo, Giuliana Decorti, Martina Fabris, Matteo Bramuzzo, Andrea Taddio, Gabriele Stocco, Patrizia Alvisi, Alessandro Ventura & Stefano Martelossi. (2019) Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study. Journal of Pediatric Gastroenterology & Nutrition 68:1, pages 37-44.
Crossref
Crossref
Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils & Séverine Vermeire. (2018) Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:11, pages 1316-1325.
Crossref
Crossref
Bella Ungar, Yoav Glidai, Miri Yavzori, Orit Picard, Ella Fudim, Avishay Lahad, Yael Haberman, Dror S. Shouval, Ilana Weintraub, Rami Eliakim, Shomron Ben-Horin & Batia Weiss. (2018) Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology & Nutrition 67:4, pages 507-512.
Crossref
Crossref
Amy Hemperly & Niels Vande Casteele. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:8, pages 929-942.
Crossref
Crossref
B Gorovits, D J Baltrukonis, I Bhattacharya, M A Birchler, D Finco, D Sikkema, M S Vincent, S Lula, L Marshall & T P Hickling. (2018) Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clinical and Experimental Immunology 192:3, pages 348-365.
Crossref
Crossref
Nicholas Carman, David R. Mack & Eric I. Benchimol. (2018) Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports 20:5.
Crossref
Crossref
Travis Piester, Adam Frymoyer, Megan Christofferson, Helen Yu, Dorsey Bass & K T Park. (2018) A Mobile Infliximab Dosing Calculator for Therapy Optimization in
Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24:2, pages 227-234.
Crossref
Crossref
Adam Frymoyer, Daniël R. Hoekman, Travis L. Piester, Tim G. de Meij, Thalia Z. Hummel, Marc A. Benninga, Angelika Kindermann & K.T. Park. (2017) Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 65:6, pages 639-645.
Crossref
Crossref
Vini Deora, Justin Kozak, Mohamed El-Kalla, Hien Q. Huynh & Wael El-Matary. (2017) Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease. Acta Paediatrica 106:11, pages 1863-1867.
Crossref
Crossref
Sara MuriasLorena MagallaresFatima Albizuri, Dora Pascual-SalcedoErwin Dreesen & Denis Mulleman. (2017) Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. Therapeutic Drug Monitoring 39:4, pages 370-378.
Crossref
Crossref
Helena Rolandsdotter, Per Marits, Ulf Sundin, Ann-Charlotte Wikström, Ulrika Fagerberg, Yigael Finkel & Michael Eberhardson. (2017) Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment. International Journal of Molecular Sciences 18:3, pages 575.
Crossref
Crossref
LB Ramsey, T Mizuno, AA Vinks & PA Margolis. (2017) Learning Health Systems as Facilitators of Precision Medicine. Clinical Pharmacology & Therapeutics 101:3, pages 359-367.
Crossref
Crossref
Laura Merras-Salmio & Kaija-Leena Kolho. (2017) Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 64:2, pages 272-278.
Crossref
Crossref
Peter Townsend & Jeffrey S. Hyams. 2017. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
95
101
.
Daniël R. Hoekman, Kay Diederen, Bart G. P. Koot, Merit M. Tabbers, Angelika Kindermann & Marc A. Benninga. (2016) Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. European Journal of Pediatrics 175:10, pages 1335-1342.
Crossref
Crossref
B. Ungar, Y. Mazor, R. Weisshof, H. Yanai, Y. Ron, I. Goren, A. Waizbard, M. Yavzori, E. Fudim, O. Picard, R. Loebstein, U. Kopylov, I. Dotan, Y. Chowers, R. Eliakim & S. Ben‐Horin. (2016) Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Alimentary Pharmacology & Therapeutics 43:12, pages 1293-1299.
Crossref
Crossref
Adam Frymoyer, Travis L. Piester & K.T. Park. (2016) Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 62:5, pages 723-727.
Crossref
Crossref